<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841502</url>
  </required_header>
  <id_info>
    <org_study_id>AKF UMCN 12.02</org_study_id>
    <nct_id>NCT01841502</nct_id>
  </id_info>
  <brief_title>Interaction Between Paroxetine and Telaprevir</brief_title>
  <acronym>ROLEX</acronym>
  <official_title>The ROLE of ParoXetine in Patients Taking Telaprevir-based Hepatitis C Therapy: Lack of a Drug-drug Interaction? (ROLEX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C (HCV) infected patients are often in need for an antidepressant. The introduction&#xD;
      of Direct Acting Antivirals such as telaprevir has greatly improved treatment outcome of HCV&#xD;
      infected patients.Telaprevir has been studied with one antidepressant, escitalopram: plasma&#xD;
      concentrations of the antidepressant were reduced by 35% and without dose adjustment this may&#xD;
      lead to inadequate treatment of depressive symptoms. There is a need for more data on&#xD;
      telaprevir drug interactions with other antidepressants.&#xD;
&#xD;
      For a number of reasons, paroxetine may be a good candidate for use together with&#xD;
      telaprevir-containing HCV treatment.&#xD;
&#xD;
      The interaction between paroxetine and telaprevir has not been studied before.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCV infected patients are often in need for an antidepressant. Inadequate treatment of&#xD;
      depression during HCV treatment has a negative effect on adherence to HCV treatment, with&#xD;
      suboptimal response as a potential result.&#xD;
&#xD;
      The introduction of Direct Acting Antivirals such as telaprevir has greatly improved&#xD;
      treatment outcome of HCV infected patients. Telaprevir, however, causes some significant&#xD;
      drug-drug interactions and hence co-administration of other medications should preferably&#xD;
      only be done based on clinical evidence that such a combination is safe.&#xD;
&#xD;
      Telaprevir has been studied with one antidepressant, escitalopram: plasma concentrations of&#xD;
      the antidepressant were reduced by 35% and without dose adjustment this may lead to&#xD;
      inadequate treatment of depressive symptoms. Dose titration of escitalopram may be needed but&#xD;
      it may take several weeks before a patient has reached a therapeutic dose.&#xD;
&#xD;
      There is a need for more data on telaprevir drug interactions with other antidepressants.&#xD;
      First, the data above show that a negative interaction occurs with escitalopram and&#xD;
      dose-titration of the antidepressant may take too long to prevent the (re-)occurrence of&#xD;
      depressive symptoms. Second, not all patients benefit from escitalopram and those with&#xD;
      (prior) treatment failure on escitalopram may require an alternative agent. Third, although&#xD;
      escitalopram is generally well-tolerated, side effects may occur and necessitate treatment&#xD;
      discontinuation. Finally, especially in the previous intravenous drug users on methadone,&#xD;
      escitalopram might not be the antidepressant of choice, since escitalopram as well as&#xD;
      methadone are drugs that can lead to QTc interval prolongation and have a risk of Torsades de&#xD;
      Pointes.&#xD;
&#xD;
      For a number of reasons, paroxetine may be a good candidate for use together with&#xD;
      telaprevir-containing HCV treatment. First, paroxetine has been shown to prevent depressive&#xD;
      symptoms in patients initiating HCV treatment with elevated depressive symptoms at baseline.&#xD;
      Second, paroxetine is an inhibitor of and is metabolized by CYP2D6 while telaprevir is an&#xD;
      inhibitor of and is metabolized by CYP3A, and therefore no drug-drug interaction is expected.&#xD;
      Third, paroxetine is one of the most widely prescribed antidepressants with a&#xD;
      well-established efficacy and safety profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Telaprevir will not be used in NL, no more inclusions are expected.&#xD;
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>paroxetine area under the curve (AUC)</measure>
    <time_frame>day -1 and day 14</time_frame>
    <description>paroxetine AUC will be compared intrasubject: day 14 + telaprevir / day -1 (without telaprevir)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>paroxetine Cmax and C24</measure>
    <time_frame>Day -1 and Day 14</time_frame>
    <description>Comparison of Cmax and C24 of paroxetine intrasubject. Day 14 (+telaprevir) / Day -1 (without telaprevir)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Day -1 to Day 28</time_frame>
    <description>Adverse events will be scored during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>short term HCV RNA response</measure>
    <time_frame>week 4</time_frame>
    <description>At week 4 HCV RNA will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>telaprevir area under the curve (AUC)</measure>
    <time_frame>Day 14</time_frame>
    <description>Telaprevir pharmacokinetics (PK) will be determined with paroxetine concomitant use. To be compared to historical data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hepatitis C Infection</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>paroxetine alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paroxetine 20 mg tablet once daily oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paroxetine + telaprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>paroxetine 20 mg once daily</description>
    <arm_group_label>paroxetine + telaprevir</arm_group_label>
    <arm_group_label>paroxetine alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telaprevir</intervention_name>
    <description>telaprevir 1125 mg twice daily</description>
    <arm_group_label>paroxetine + telaprevir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is at least 18 and not older than 65 years at screening.&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          -  Subject has a chronic HCV infection with genotype 1.&#xD;
&#xD;
          -  Subject is eligible for telaprevir containing HCV treatment.&#xD;
&#xD;
          -  Subject is on a stable dose of 20 mg paroxetine once daily for at least 4 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.&#xD;
&#xD;
          -  Pregnant female (as confirmed by a human chorionic gonadotropin (HCG) test performed&#xD;
             less than 6 weeks before Day -1) or breast-feeding female. Female subjects of&#xD;
             childbearing potential without adequate contraception, e.g. hysterectomy, bilateral&#xD;
             tubal ligation, (non-hormonal) intrauterine device, total abstinence, double barrier&#xD;
             methods, or two years post-menopausal. They must agree to take precautions in order to&#xD;
             prevent a pregnancy throughout.&#xD;
&#xD;
          -  Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          -  Inability to understand the nature and extent of the trial and the procedures&#xD;
             required.&#xD;
&#xD;
          -  Participation in a drug trial within 60 days prior to the first dose of telaprevir.&#xD;
&#xD;
          -  Use of relevant concomitant medication, as assessed by a hospital pharmacist (member&#xD;
             of the study team).&#xD;
&#xD;
          -  Hemoglobin &lt; 12 g/dL (females) or &lt; 13 g/dL (males) (7.4 respectively 8.0 mM).&#xD;
&#xD;
          -  Poor- or ultrarapid metabolizer CYP2D6 (based on genetic testing)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Burger, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Centre Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GGD Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Groep</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstadziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://repository.ubn.ru.nl/handle/2066/142579</url>
    <description>dissertation page 185-192</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2013</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>telaprevir</keyword>
  <keyword>paroxetine</keyword>
  <keyword>interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

